Nxera Pharma Co Ltd (SOLTF)
9.15
0.00 (0.00%)
USD |
OTCM |
Sep 27, 16:00
Nxera Pharma Cash from Financing (Quarterly): -10.15M for June 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -10.15M |
| March 31, 2024 | -12.29M |
| December 31, 2023 | 70.34M |
| September 30, 2023 | 274.90M |
| June 30, 2023 | -0.3937M |
| March 31, 2023 | -0.3861M |
| December 31, 2022 | -2.485M |
| September 30, 2022 | 1.905M |
| June 30, 2022 | -36.50M |
| March 31, 2022 | -0.396M |
| December 31, 2021 | -0.2974M |
| September 30, 2021 | 97.55M |
| June 30, 2021 | 2.260M |
| March 31, 2021 | 1.860M |
| December 31, 2020 | -4.856M |
| September 30, 2020 | 196.21M |
| June 30, 2020 | 0.5621M |
| March 31, 2020 | -1.938M |
| December 31, 2019 | -44.56M |
| September 30, 2019 | -4.251M |
| June 30, 2019 | -11.03M |
| March 31, 2019 | -4.059M |
| September 30, 2018 | -5.844M |
| June 30, 2018 | -7.793M |
| March 31, 2018 | -5.032M |
| Date | Value |
|---|---|
| December 31, 2017 | 180.11M |
| September 30, 2017 | -10.33M |
| June 30, 2017 | 39.59M |
| March 31, 2017 | -13.58M |
| December 31, 2016 | 4.644M |
| September 30, 2016 | -44.40M |
| June 30, 2016 | -5.018M |
| March 31, 2016 | -6.095M |
| December 31, 2015 | 26.01M |
| September 30, 2015 | -12.43M |
| June 30, 2015 | -0.2968M |
| March 31, 2015 | 181.39M |
| December 31, 2014 | 0.1189M |
| September 30, 2014 | 0.1347M |
| June 30, 2014 | |
| March 31, 2014 | 43.15M |
| December 31, 2013 | 0.0649M |
| September 30, 2013 | 0.095M |
| June 30, 2013 | 0.3694M |
| March 31, 2011 | 0.2468M |
| December 31, 2010 | 0.00 |
| September 30, 2010 | 0.00 |
| June 30, 2010 | 0.00 |
| March 31, 2010 | -0.0007M |
| December 31, 2009 | 0.0223M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-44.56M
Minimum
Dec 2019
274.90M
Maximum
Sep 2023
26.35M
Average
-0.3899M
Median
Cash from Financing (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 2.030B |
| PeptiDream Inc | -4.424M |
| Healios KK | 8.664M |
| AnGes Inc | -- |
| SanBio Co Ltd | 2.166M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 24.55M |
| Cash from Investing (Quarterly) | 3.121M |
| Free Cash Flow | -11.37M |
| Free Cash Flow Per Share (Quarterly) | 0.2699 |
| Free Cash Flow to Equity (Quarterly) | 59.32M |
| Free Cash Flow to Firm (Quarterly) | 24.21M |
| Free Cash Flow Yield | -1.44% |